The rapid reduction in cardiac events with lipid-lowering therapy: Mechanisms and implications
Open Access
- 1 November 1993
- journal article
- editorial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 72 (14) , 1072-1073
- https://doi.org/10.1016/0002-9149(93)90864-9
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factorsThe American Journal of Cardiology, 1993
- Should We Be Measuring Blood Cholesterol Levels in Young Adults?Published by American Medical Association (AMA) ,1993
- Health policy on blood cholesterol. Time to change directions.Circulation, 1992
- Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity.Circulation, 1992
- Cholesterol lowering as a treatment for established coronary heart disease.Circulation, 1992
- Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)The Lancet, 1992
- Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein BNew England Journal of Medicine, 1990
- Published by Massachusetts Medical Society ,1990
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984